Pereira JB, Janelidze S, Stomrud E, et al. - Experts aspired to explore whether plasma biomarkers can predict changes in amyloid load, tau accumulation, brain atrophy, and cognition in non-demented people. Plasma amyloid-β 42/40 (Aβ42/40), phosphorylated-tau181 (P-tau181), phosphorylated-tau217 (P-tau217), and neurofilament light were determined in 159 non-demented people, 123 Alzheimer disease (AD) dementia patients and 35 non-AD dementia patients from the Swedish BioFINDER-2 study, who underwent longitudinal amyloid (18 F-flutemetamol) and tau (18 F-RO948) positron emission tomography, structural magnetic resonance imaging (T1-weighted) and cognitive testing. The findings suggest that plasma A42/40 and P-tau217 may be useful as prognostic markers of future AD pathology in clinical practice, research, and drug development.